Why Is ARCUTIS BIOTHERAPEUT (ARQT) Stock Up Today?
By the Top Tier Newswire AI Desk · October 9, 2026 at 12:04 PM ET · reviewed against 3 wire stories
ARCUTIS BIOTHERAPEUT (ARQT) is up +7.39% in the latest session. Our newswire has captured 3 stories on ARQT across 3 sources in the last 36 hours, with AI sentiment reading bullish (avg 63/100).
Public view, delayed 4h. Every headline, price and sentiment read below — and this write-up itself — reaches Pro subscribers live. Public readers see it once it clears the delay.
Arcutis Biotherapeutics stock (ARQT) rose 7.39% to $26.30 on Wednesday. The primary driver was the presentation of new clinical data for its ZORYVE (roflumilast) portfolio at the European Academy of Dermatology and Venereology congress. The data highlighted rapid itch relief and broad efficacy across atopic dermatitis, psoriasis, and seborrheic dermatitis.
What Happened
Arcutis presented results from the Phase 2 INTEGUMENT-INFANT trial, which evaluated ZORYVE cream 0.05% in infants aged 3 to under 24 months. The study reported a 34.4% vIGA-AD Success rate at Week 4, a significant finding given the limited treatment options currently available for this patient population. The company also shared new analyses from the ARRECTOR and DERMIS-1/2 trials, further supporting the drug’s utility.
In related regulatory news, Arcutis Canada secured Health Canada approval for roflumilast cream in pediatric atopic dermatitis patients. Analysts responded positively to the data. Morgan Stanley maintained its Overweight rating on the stock and raised its price target to $38. Guggenheim also maintained a Buy rating and raised its price target to $38.
What The Data Shows
The stock opened at $24.70, a 0.9% gap up from the prior close of $24.49. It reached a session high of $26.41 at 11:55 AM ET before settling near $26.38. Volume was 0.4 million shares, which is 0.2 times the three-month daily average. The stock printed 42 fresh 52-week highs on October 9, 2026, extending its recent upward momentum.
Fundamentals show a market cap of $3.0 billion and a trailing P/E of 113.7. Revenue grew 76.1% over the trailing twelve months, and the net margin stands at 6.1%. The stock has a beta of 1.58 and trades within a 52-week range of $19.30 to $31.77. Recent insider activity has been predominantly selling, with 11 sales totaling $2.1 million in the last 90 days and no buys recorded.
What To Watch
Investors will monitor how the market digests the pediatric approval in Canada and the broader ZORYVE data. The upcoming earnings date is not provided in the current data set, so attention will likely remain on analyst price target revisions and further regulatory updates.
AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Public view is delayed 4 hours from real time. Not financial advice.
ARQT · today's session (5-min) · +8.53% vs prior close · updated 5:45 PM ETAI sentiment, last 36h · averaged over 3 stories · 63/100 bullish
The headlines behind the move
Story flow · 3 stories on the wire, last 36h · hover or tap a dot for the headline
5h agoMarketChameleonBULLISH 74Product/PR
ARQT rallies after new ZORYVE infant and psoriasis data highlight rapid itch relief and broad efficacy
October 9, 2026
Arcutis (ARQT) presented new ZORYVE (roflumilast) data across atopic dermatitis, psoriasis, and seborrheic dermatitis, including Phase 2 INTEGUMENT-INFANT results showing 34.4% vIGA-AD Success at Week 4 and caregiver-reported itch improvement within 10 minutes in 46.6% of infants. The update also highlighted psoriasis readouts from ARRECTOR showing higher clear/almost clear rates versus vehicle at Week 8 and new real-world survey findings pointing to flare-driven topical corticosteroid use and…
9h agoThe FlyBULLISH 58Product/PR
Arcutis Biotherapeutics presents data across Zoryve portfolio
9h agoBusiness InsiderBULLISH 58Product/PR
Arcutis Presents ZORYVE® (roflumilast) Data and Real-World Topical Corticosteroid Research at EADV and Fall Clinical
Presentation of data from the INTEGUMENT-INFANT trial of investigational ZORYVE cream 0.05% in infants ages 3 to <24 months, where treatment options remain limited New analyses from the ARRECTOR and DERMIS-1/2 trials further...
Want the next move before the crowd? The live terminal streams every headline in real time with watchlist alerts, AI sentiment, and the full data stack behind this page.Get Pro Access →